Startup Spotlight: Arterys’ AI-powered medical imaging
![](https://assets.bizclikmedia.net/138/958b5ccdf779275a004221a682ad87ff:1433b4cde8de4a72e40c89d5c5616f50/404mwc24kbqa7cce-undefined-jpeg.webp)
San Francisco’s Arterys operates a cloud-native medical imaging platform powered by AI.
Intended to improve the speed of diagnoses and the ease of collaboration, Arterys’ platform scales to deliver computational power on demand, with AI applications assisting radiologists with such tasks as tracking lung lesions and examining heart function.
Since its foundation in 2016, the company has raised $71.7mn across nine funding rounds. Last month, the company’s latest Series C saw the company raise $28mn from lead investors the Singaporean government-owned Temasek Holdings and Benslie Investment Group. Also participating were Revelation Partners, Fosun Capital, Emergent Medical Partners and Varian Medical Systems.
In a press release, Henry Weinstein, Managing Partner at Benslie International, said: "The current crisis has shown us the necessity of a different approach to providing healthcare, where technology and AI are crucial for future success. Arterys is committed to transforming the way AI is integrated into the medical workflow, a promise that is long due in the industry. We recently launched our cloud platform and marketplace that will consolidate the work of thousands of AI models to be readily available for use by healthcare institutions around the globe”
The company’s core products include Cardio AI and Lung AI. The former uses deep learning to process images and generate reports to assist with the examination of heart defects. The latter can automatically detect the presence of nodules within the lungs, which the company said reduced missed detections by between 42 and 70%.
Newly appointed acting CEO and co-founder John Acerio-Cilies, said: “We realize that we can't transform the healthcare system alone," says Axerio-Cilies. "No company can. And now, the same technology and strengths that we've leveraged to build our core products are now available to medical innovators at companies and universities around the world — they can benefit from regulatory support, channel partnerships, performance, security, and best-in-class hospital system integrations."